Antiviral methods

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

514 13, 514 14, 514 15, 514 16, 514 17, 4241851, 530324, 530325, 530326, 530327, 530328, 530329, 530350, 530395, 530402, 530345, A61K 3804, A61K 3808, A61K 3810, A61K 3816

Patent

active

061302023

ABSTRACT:
Methods for inhibiting infectivity and reducing infection by human rhinovirus (HRV) of host cells susceptible to infection by HRV and methods of inhibiting initiation and spread of the common cold, said methods comprising contacting HRV under conditions favorable for binding with a multimeric antiviral agent comprising two or more units wherein said units may be the same or different and are each independently selected from the group consisting of transmembrane intercellular adhesion molecule-1 (tmICAM-1) and truncated forms of intercellular adhesion molecule-1 (tICAMs), each of said units containing at least one unpaired cysteine residue at a position selected from the group consisting of 307 and 309, wherein each of said units is linked to at least one other of said units via a disulfide bridge, and wherein said multimeric antiviral agent binds to HRV and reduces infectivity thereof.

REFERENCES:
patent: 5081228 (1992-01-01), Dower et al.
patent: 5179017 (1993-01-01), Axel et al.
patent: 5235049 (1993-08-01), McClelland et al.
patent: 5240694 (1993-08-01), Gwaltney, Jr.
patent: 5284931 (1994-02-01), Springer et al.
patent: 5304636 (1994-04-01), Blaas et al.
patent: 5324510 (1994-06-01), Wegner et al.
patent: 5340800 (1994-08-01), Liu et al.
patent: 5349053 (1994-09-01), Landolfi
patent: 5359046 (1994-10-01), Capon et al.
patent: 5372933 (1994-12-01), Zamarron et al.
patent: 5395929 (1995-03-01), Corbi et al.
patent: 5422097 (1995-06-01), Gwaltney
patent: 5472849 (1995-12-01), Rothlein et al.
patent: 5475091 (1995-12-01), Springer et al.
patent: 5525487 (1996-06-01), Gallatin et al.
patent: 5532127 (1996-07-01), Gallatin et al.
patent: 5580969 (1996-12-01), Hoke et al.
patent: 5589453 (1996-12-01), Greve
patent: 5597567 (1997-01-01), Whitcup et al.
patent: 5603932 (1997-02-01), Blaas et al.
patent: 5612216 (1997-03-01), Springer et al.
patent: 5663293 (1997-09-01), Gallatin et al.
patent: 5674982 (1997-10-01), Greve et al.
patent: 5686581 (1997-11-01), Greve et al.
patent: 5686582 (1997-11-01), Greve et al.
patent: 5712245 (1998-01-01), Blaas et al.
patent: 5730983 (1998-03-01), Wegner et al.
patent: 5821341 (1998-10-01), McClelland et al.
patent: 5831036 (1998-11-01), Springer et al.
patent: 5849699 (1998-12-01), McClelland et al.
patent: 5871733 (1999-02-01), Greve et al.
Pepinsky, R.B. et al. J.B.C., 266(27):18244-49 (1991) "The Increased Potency of Cross-linked Lymphocyte Function-associated Antigen-3 (LFA-3) Mutimers is a Direct Consequence of Changes in Valency."
Dustin, M.L., et al. J. Immunology 137(1):245-254 (1986). Induction by IL-1 and Interferon-gamma Tissue Distribution, Biochemistry, and Function of a Natural Adherence Molecule (ICAM1).
Dustin, M.L., et al., J. Exp. Med. 169:503-517 (1989), "Correlation of CUZ Binding and Functional Properties of Multimeric and Monomeric Lymphocyte Function-associated Antigen 3."
Rothlein, R. et al., J. Immunol. 137(4):1270-1274 (1986). "A Human Intercellular Adhesion Molecule (ICAM-1) Distinct from LFA-1."
Tomassini, J.E., et al. J. Virology, 58(2):290-295 (1986). "Isolation of a Receptor Protein Involved in Attachment of Human Rhinovirus."
Al-Nakib, W., P.G. Higgins, G.I. Barrow, D.A.J. Tyrrell, K. Andries, G. Vanden Bussche, N. Taylor, and P.A.J. Janssen, "Suppression of Colds in Human Volunteers Challenged with Rhinoviurs by a New Synthetic Drug (R61837)", Antimicrobial Agents and Chemotherapy 33(4): 522-525 (Apr. 1989).
Amzel, L. M., and R.J. Poljak, "Three Dimensional Structure of Immunoglobulins", Ann. Rev. Biochem. 48: 961-997 (1979).
Becker, J. W., and G.N.Reeke, Jr., "Three-dimensional structure of .beta..sub.2 -microglobulin", Proc. Natl. Acad. Sci. USA 82: 4225-4229 (Jun. 1985).
Becker, J. W., H.P. Erickson, S. Hoffman, B.A. Cunningham, and G.M. Edelman, "Topology of cell adhesion molecules", Proc. Natl. Acad. Sci. USA, 86: 1088-1092 (Feb. 1989).
Bjorkman, P. J., M.A. Saper, B. Samraoui, W.S. Bennett, J.L. Strominger, and D.C. Wiley, "Structure of the human class I histocompatibility antigen, HLA-A2", Nature 329: 506-512 (Oct. 1987).
Colman, P.M., "Structure of Antibody-Antigen Complexes: Implications for Immune Recognition", Advances in Immunology 43: 99-132 (1988).
Colonno, R. J., J.H. Condra, S. Mizutani, P.L. Callahan, M.-E.Davies, and M.A. Murcko, "Evidence for the direct involvement of the rhinovirus canyon in receptor binding", Proc. Natl. Acad. Sci. USA 85: 5449-5453 (Aug. 1988).
Craig, A. G. and A.R. Berendt, "The Role of ICAM-1 as a Receptor for Rhinovirus and Malaria", in Integrins and ICAM-1 in Immune Responses, N. Hodd, ed. (Chem Immunol. Basel, Karger, 1991), vol. 50, pp. 116-134 (1991).
Crump, C. E., E. Arruda, and F.G. Hayden, "Comparative Antirhinoviral Activities of Soluble Intercellular Adhesion Molecule-1 (sICAM-1) and Chimeric ICAM-1/Immunoglobulin A Molecule", Antimicrobial Agents and Chemotherapy 38(6): 1425-1427 (Jun. 1994).
Dayhoff, M. O., W.C. Barker, and L.T. Hunt, "Establishing Homologies in Protein Sequences", Methods in Enzymology 91: 524-545 (1983).
Dearden, C., W. Al-Nakib, K. Andries, R. Woestenborghs, and D.A.J. Tyrrell, "Drug resistant rhinoviruses from the nose of experimentally treated volunteers", Arch. Virol. 109: 71-81 (1989).
Dustin, M. L. and T.A. Springer, "Lymphocyte Function-associated Antigen-1 (LFA-1) Interaction with Intercellular Adhesion Molecule-1 (ICAM-1) is One of At Least Three Mechanisms for Lymphocyte Adhesion to Cultured Endothelial Cells", J. Cell Biol. 107: 321-331 (Jul. 1988).
Ezekovitz, R.A.B., R.B. Sim, G.G. MacPherson, and S. Gordon, "Interaction of Human Monocytes, Macrophages, and Polymorphonuclear Leukocytes with Zymosan in Vitro: Role of Type 3 Compliment Receptors and Macrophage Derived Complement", J. Clin. Invest. 76: 2368-2376 (Dec. 1985).
Greve, J. M., C.P. Forte, C.W. Marlor, A.M. Meyer, H. Hoover-Litty, D. Wunderlich, and A. McClelland, "Mechanisms of Receptor-Mediated Rhinovirus Neutralization Defined by Two Soluble Forms of ICAM-1", J. Virol. 65(11): 6015-6023 (Nov. 1991).
Guttman, N., and D. Baltimore, "Plasma Membrane Component Able to Bind and Alter Virions of Poliovirus Type 1: Sutides on Cell-Free Alteration Using a Simplified Assay", Virol. 82: 25-36 (1977).
Gwaltney, J. M., Jr. and J.O. Hendley, "Rhinovirus Transmission: One if by Air, Two if by Hand", Trans. Am. Clin. Climatol. Assoc. 89: 194-200 (1977).
Gwaltney, J. M.,Jr., and J.O. Hendley, "Rhinovirus Transmission One if by Air, Two if by Hand", Am. J. Epid. 107(5): 357-361 (May 1978).
Gwaltney, J. M., Jr., "Rhinovirus colds: epdimiology, clinical characteristics and transmission", Eur. J. Respir. Dis. 64 (suppl. 128): 336-339 (1983).
Gwaltney, J. M., Jr., "Rhinoviruses", Yale J. Biol. Med. 48: 17-45 (1975).
Hayden, F. G., and J.M. Gwaltney, Jr., "Intranasal Interferon-.alpha..sub.2 Treatment of Experimental Rhinoviral Colds", J. Infect. Dis. 150(2): 174-180 (Aug. 1984).
Hendley, J. O., and J.M. Gwaltney, Jr., "Mechanisms of Transmission of Rhinovirus Infections", Epidemologic Reviews 10: 242-258 (1988).
Horley, K. J., C. Carpenito, B. Baker, and F. Takei, "Molecular cloning of murine intercellular adhesion molecule (ICAM-1)", EMBO J. 8(10): 2889-2896 (1989).
Jacobs, K., C. Shoemaker, R. Rudersdorf, S.D. Neill, R.J. Kaufman, A. Mufson, J. Seehra, S.S. Jones, R. Hewick, E.F. Fritsch, M. Kawakita, T. Shimizu, and T. Miyake, "Isolation and characterization of genomic and cDNA clones of human erythropoietin", Nature 313: 806-810 (Feb. 1985).
Kim S., T.J. Smith, M.S. Chapman, M.G. Rossmann, D.C. Pevear, F.J. Dutko, P.J. Felock, G.D. Diana, and M.A. McKinlay, "Crystal Structure of Human Rhinovirus Serotype 1A (HRV1A)", J. Med. Biol. 210: 91-111 (1989).
Layne, S. P., M.J. Merges, M. Dembo, J.L. Spouge, and P.L. Nara, "HIV requires multiple gp120 molecules for CD4-mediated infection", Nature 346: 277-279 (Jul. 1990).
Leonard, W. J., J.M. Depper, G.R. Crabtree, S. Rudikoff, J. Pumphrey, R.J. Robb, M. Kronke, P.B. Svetlik, N.J. Peffer, T.A. Waldmann, and W.C. Greene, "Molecular cloning and expression of cDNAs for the human interleukin-2 receptor", Nature 311: 626-631 (Oct. 1984).
Leszczynsk

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Antiviral methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antiviral methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antiviral methods will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2257071

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.